HemaSphere : Impact Factor & More
eISSN: 2572-9241pISSN: 2572-9241
Open AccessShare this on:
Key Metrics
CiteScore 
5.4
Impact Factor
5 - 10
Scite Index
0.90 5-Year SI
SJR
Q3Hematology
SNIP
0.9
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on HemaSphere
HemaSphere Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 1200 |
| Publication Time | 7 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Hematology Association |
| Frequency | Monthly |
| Publication Start Year | 2017 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Other charges | Visit website |
| Publication Time | 7 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC, CC BY-SA, CC BY-NC-ND, CC BY-ND, CC BY-NC-SA |
| OA statement | Visit website |
View less
Planning to publish in HemaSphere ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in HemaSphere
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
- 8 Dec 2025
- HemaSphere
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR‐T therapy
- 8 Dec 2025
- HemaSphere
TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
- 1 Dec 2025
- HemaSphere
Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
- 1 Dec 2025
- HemaSphere
A paradigm shift in neutrophil adverse event grading: What now?
- 1 Dec 2025
- HemaSphere
MMS22L is a novel key actor of normal and pathological erythropoiesis
- 1 Dec 2025
- HemaSphere
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
- 8 Dec 2025
- HemaSphere
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR‐T therapy
- 8 Dec 2025
- HemaSphere
TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
- 1 Dec 2025
- HemaSphere
Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
- 1 Dec 2025
- HemaSphere
A paradigm shift in neutrophil adverse event grading: What now?
- 1 Dec 2025
- HemaSphere
MMS22L is a novel key actor of normal and pathological erythropoiesis
- 1 Dec 2025
- HemaSphere
FAQs on HemaSphere
How long has HemaSphere been actively publishing? 
What is the publishing frequency of HemaSphere?
How many articles did HemaSphere publish last year?
What is the eISSN & pISSN for HemaSphere?
What is Citescore for HemaSphere?
What is SNIP score for HemaSphere?
What is the SJR for HemaSphere?
Who is the publisher of HemaSphere?
